ASCO Confab: Who's Grabbing the Spotlight?

Editor's note: This article compiles some of the major stories that emerged over the weekend at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla. The following items were reported by TheStreet.com's Althea Chang and first appeared in the Columnist Conversation on RealMoney from May 14-16. Althea will continue to monitor events from Florida until the conclusion of the conference.

ASCO Update

Genentech's (DNA Quote) Avastin improved lung cancer survival when added to standard combination chemotherapy, according to research presented at this year's meeting of the American Society of Clinical Oncology. Avastin delayed disease progression and allowed for longer survival of non-small cell lung cancer patients, according to the research.

In a phase III trial comparing the use of paclitaxel and carboplatin, with and without Avastin, patients who received Avastin experienced cancer progression two months later and lived more than two months longer than patients who did not. ...